In Vitro Diagnostics Market Projected to Hit $170B by 2031, Driven by Molecular and Point-of-Care Innovations — Wissen Research LLC

Event summary

The global in vitro diagnostics (IVD) market is projected to grow from $117.39B in 2026 to $170.10B by 2031, a CAGR of 7.7%.
Molecular diagnostics is the fastest-growing segment, with a CAGR of 14.7%, driven by advancements in PCR, sequencing, and other nucleic acid-based techniques.
Point-of-care testing and portable diagnostic platforms are enabling faster clinical decision-making in hospitals, emergency departments, and home-care settings.
Reagents and kits held the largest revenue share by product in 2025, at approximately 70%, reflecting their role as a recurring, consumable component of every diagnostic test performed.
North America held the largest regional share in 2025, at approximately 39%, supported by advanced healthcare infrastructure and the presence of major IVD companies.

The big picture

The IVD market is being reshaped by the convergence of molecular diagnostics, point-of-care testing, and AI-enabled digital pathology. The shift toward decentralized testing and the rising burden of chronic and infectious diseases are driving sustained demand. Strategic acquisitions, such as Danaher's purchase of Masimo's non-invasive patient monitoring business and Roche's acquisition of PathAI, highlight the industry's focus on integrating advanced technologies to capture recurring reagent and consumable demand.

What we're watching

Technology Leadership: Whether molecular diagnostics can sustain its rapid growth pace and maintain dominance in infectious disease testing, oncology, and genetic testing.
Regulatory Hurdles: The impact of stringent regulatory requirements and complex reimbursement pathways on the speed of new diagnostic test launches.
Market Consolidation: The pace at which large diagnostics companies will continue to acquire AI and digital pathology capabilities to strengthen their market presence.